CRNX
Crinetics Pharmaceuticals, Inc.NASDAQHealthcare$37.23+1.26%ClosedMarket Cap: $3.90B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
3.57
P/S
728.30
EV/EBITDA
-7.76
DCF Value
$-7.32
FCF Yield
-9.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
108.5%
Operating Margin
-9534.5%
Net Margin
-8585.2%
ROE
-41.5%
ROA
-41.0%
ROIC
-48.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $3.9M | 111.8% | $-133.7M | $-122.8M | $-1.30 | — |
| FY 2025 | $7.7M | 35.5% | $-516.8M | $-465.3M | $-4.95 | — |
| Q3 2025 | $143.0K | 100.0% | $-142.6M | $-130.1M | $-1.38 | — |
| Q2 2025 | $1.0M | 100.0% | $-129.1M | $-115.6M | $-1.23 | — |
| Q1 2025 | $361.0K | 100.0% | $-111.4M | $-96.8M | $-1.04 | — |
| Q4 2024 | $0.00 | NaN% | $-94.7M | $-80.6M | $-0.88 | — |
| FY 2024 | $1.0M | 100.0% | $-338.9M | $-298.4M | $-3.69 | — |
| Q3 2024 | $0.00 | NaN% | $-87.8M | $-76.8M | $-0.96 | — |
| Q2 2024 | $399.0K | 100.0% | $-82.8M | $-74.1M | $-0.94 | — |
| Q1 2024 | $640.0K | 100.0% | $-73.5M | $-66.9M | $-0.93 | — |
| Q4 2023 | $0.00 | NaN% | $-62.7M | $-60.1M | $-0.89 | — |
| FY 2023 | $4.0M | 100.0% | $-222.6M | $-214.5M | $-3.69 | — |